

## **Part VI: Summary of the risk management plan**

### Summary of risk management plan for DIPRIMIS/NODIGAP (colecalciferol)

This is a summary of the risk management plan (RMP) for DIPRIMIS/NODIGAP. The RMP details important risks of DIPRIMIS/NODIGAP, how these risks can be minimised, and how more information will be obtained about DIPRIMIS's/NODIGAP's risks and uncertainties (missing information).

DIPRIMIS's/NODIGAP's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how DIPRIMIS/NODIGAP should be used.

Important new concerns or changes to the current ones will be included in updates of DIPRIMIS's/NODIGAP's RMP.

#### **I. The medicine and what it is used for**

DIPRIMIS/NODIGAP is authorised for prevention and treatment of vitamin D deficiency in adults and children aged 12 to 18 years. It contains colecalciferol as the active substance and it is given by oral route of administration.

#### **II. Risks associated with the medicine and activities to minimise or further characterise the risks**

Important risks of DIPRIMIS/NODIGAP, together with measures to minimise such risks and the proposed studies for learning more about DIPRIMIS's/NODIGAP's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g., with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

## **II.A List of important risks and missing information**

Important risks of DIPRIMIS/NODIGAP are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely administered. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of DIPRIMIS/NODIGAP. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g., on the long-term use of the medicine).

<b>List of important risks and missing information</b>	
Important identified risks	None
Important potential risks	None
Missing information	None

## **II.B Summary of important risks**

The safety information in the proposed Product Information is aligned to the reference medicinal product.

## **II.C Post-Authorization Development Plan**

### **II.C.1 Studies which are conditions of the marketing authorisation**

There are no studies which are conditions of the marketing authorisation or specific obligation of DIPRIMIS/NODIGAP.

### **II.C.2 Other studies in post-authorisation development plan**

There are no studies required for DIPRIMIS/NODIGAP.